Equipotent Inhibition of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase - Dual Targets of the Endocannabinoid System to Protect against Seizure Pathology

Neurotherapeutics

Volumn 9, Issue 4, 2012, Pages 801-813

  Naidoo, Vinogran ^a   Karanian, David A ^b,c   Vadivel, Subramanian K ^c   Locklear, Johnathan R ^a   Wood, JodiAnne T ^c   Nasr, Mahmoud ^c   Quizon, Pamela Marie P ^a   Graves, Emily E ^a   Shukla, Vidyanand ^c   Makriyannis, Alexandros ^c   Bahr, Ben A ^a,b  

^a UNIVERSITY OF NORTH CAROLINA AT PEMBROKE   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c NORTHEASTERN UNIVERSITY   (United States)

Author keywords

AM6701; Amphiphysin I; Endocannabinoid modulation; Excitotoxicity; GluA1; Neuroprotection

Indexed keywords

5 [(1,1' BIPHENYL) 4 YLMETHYL] N,N DIMETHYL 2H TETRAZOLE 2 CARBOXAMIDE; ACYLGLYCEROL LIPASE; AM 6701; CALPAIN; ENDOCANNABINOID; FATTY ACID AMIDASE; KAINIC ACID; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; CYTOSKELETON; DEGENERATIVE DISEASE; DRUG TARGETING; EXCITOTOXICITY; IN VIVO STUDY; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE;

AMIDOHYDROLASES; ANIMALS; CONVULSANTS; ENDOCANNABINOIDS; ENZYME INHIBITORS; HIPPOCAMPUS; IMMUNOBLOTTING; MALE; MONOACYLGLYCEROL LIPASES; NEURONS; ORGAN CULTURE TECHNIQUES; RATS; RATS, SPRAGUE-DAWLEY; SEIZURES; TETRAZOLES;

EID: 84862065791     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-011-0100-y     Document Type: Article

References (74)

1. Hwang J, Adamson C, Butler D, Janero DR, Makriyannis A, Bahr BA. Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality. Life Sci 2010; 86: 615-623.
2. Zanettini C, Panlilio LV, Alicki M, et al. Effects of endocannabinoid system modulation on cognitive and emotional behavior. Front Behav Neurosci 2011; 5: 57.
3. Pacher P, Hasko G. Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 2008; 153: 252-262.
4. Janero DR, Vadivel SK, Makriyannis A. Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategies. Int Rev Psychiatry 2009; 21: 122-133.
5. Chen X, Zhang J, Chen C. Endocannabinoid 2-arachidonoylglycerol protects neurons against β-amyloid insults. Neuroscience 2011; 178: 159-168.
6. Benito C, Nunez E, Tolon RM, et al. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci 2003; 23: 11136-11141.
7. Maccarrone M, Gubellini P, Bari M, et al. Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J Neurochem 2003; 85: 1018-1025.
8. Pisani V, Madeo G, Tassone A, et al. Homeostatic changes of the endocannabinoid system in Parkinson's disease. Mov Disord 2011; 26: 216-222.
9. Mievis S, Blum D, Ledent C. Worsening of Huntington disease phenotype in CB1 receptor knockout mice. Neurobiol Dis 2011; 42: 524-529.
10. Micale V, Mazzola C, Drago F. Endocannabinoids and neurodegenerative diseases. Pharmacol Res 2007; 56: 382-392.
11. Ludanyi A, Eross L, Czirjak S, et al. Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus. J Neurosci 2008; 28: 2976-2990.
12. Parmentier-Batteur S, Jin K, Mao XO, et al. Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J Neurosci 2002; 22: 9771-9775.
13. Karanian DA, Brown QB, Makriyannis A, Kosten TA, Bahr BA. Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity. J Neurosci 2005; 25: 7813-7820.
14. Karanian DA, Karim SL, Wood JT, et al. Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage. J Pharmacol Exp Ther 2007; 322: 1059-1066.
15. Hajos N, Katona I, Naiem SS, et al. Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur J Neurosci 2000; 12: 3239-3249.
16. Kreitzer AC, Regehr WG. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 2001; 29: 717-727.
17. Ohno-Shosaku T, Maejima T, Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 2001; 29: 729-738.
18. Wilson RI, Kunos G, Nicoll RA. Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron 2001; 31: 453-462.
19. Deadwyler SA, Hampson RE, Mu J, et al. Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process. J Pharmacol Exp Ther 1995; 273: 734-743.
20. Gomez del Pulgar T, Velasco G, Guzman M. The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem J 2000; 347: 369-373.
21. Molina-Holgado F, Pinteaux E, Heenan L, et al. Neuroprotective effects of the synthetic cannabinoid HU-210 in primary cortical neurons are mediated by phosphatidylinositol 3-kinase/AKT signaling. Mol Cell Neurosci 2005; 28: 189-194.
22. Galve-Roperh I, Rueda D, Gomez del Pulgar T, et al. Mechanism of extracellular signal-regulated kinase activation by the CB1 cannabinoid receptor. Mol Pharmacol 2002; 62: 1385-1392.
23. Basavarajappa BS. Critical enzymes involved in endocannabinoid metabolism. Protein Pept Lett 2007; 14: 237-246.
24. Vandevoorde S, Lambert DM. The multiple pathways of endocannabinoid metabolism: a zoom out. Chem Biodivers 2007; 4: 1858-1881.
25. Di Marzo V. Endocannabinoids: synthesis and degradation. Rev Physiol Biochem Pharmacol 2008; 160: 1-24.
26. Ahn K, McKinney MK, Cravatt BF. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 2008; 108: 1687-1707.
27. Egertova M, Cravatt BF, Elphick MR. Comparative analysis of fatty acid amide hydrolase and CB1 cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience 2003; 119: 481-496.
28. Egertova M, Giang DK, Cravatt BF, et al. A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc Biol Sci 1998; 265: 2081-2085.
29. Gulyas AI, Cravatt BF, Bracey MH, et al. Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci 2004; 20: 441-458.
30. Dinh TP, Carpenter D, Leslie FM, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 2002; 99: 10819-10824.
31. Hansen HH, Schmid PC, Bittigau P, et al. Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J Neurochem 2001; 78: 1415-1427.
32. Marsicano G, Goodenough S, Monory K, et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003; 302: 84-88.
33. Naidoo V, Nikas SP, Karanian DA, et al. A new generation fatty acid amide hydrolase inhibitor protects against kainate-induced excitotoxicity. J Mol Neurosci 2011; 43: 493-502.
34. Hampson RE, Miller F, Palchik G, Deadwyler SA. Cannabinoid receptor activation modifies NMDA receptor mediated release of intracellular calcium: implications for endocannabinoid control of hippocampal neural plasticity. Neuropharmacology 2011; 60: 944-952.
35. Onaivi ES. Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications. Int Rev Neurobiol 2009; 88: 335-369.
36. Araujo BH, Torres LB, Cossa AC, et al. Hippocampal expression and distribution of CB1 receptors in the Amazonian rodent Proechimys: an animal model of resistance to epilepsy. Brain Res 2010; 1335: 35-40.
37. Alexander JP, Cravatt BF. Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes. Chem Biol 2005; 12: 1179-1187.
38. Vanderklish PW, Bahr BA. The pathogenic activation of calpain: A marker and mediator of cellular toxicity and disease states. Internatl J Exp Pathol 2000; 81: 323-339.
39. Bahr BA, Tiriveedhi S, Park GY, Lynch G. Induction of calpain-mediated spectrin fragments by pathogenic treatments in long-term hippocampal slices. J Pharmacol Exp Ther 1995; 273: 902-908.
40. Ramarao MK, Murphy EA, Shen MW, et al. A fluorescence-based assay for fatty acid amide hydrolase compatible with high-throughput screening. Anal Biochem 2005; 343: 143-151.
41. Patricelli MP, Lashuel HA, Giang DK, et al. Comparative characterization of a wild type and transmembrane domain-deleted fatty acid amide hydrolase: identification of the transmembrane domain as a site for oligomerization. Biochemistry 1998; 37: 15177-15187.
42. Zvonok N, Pandarinathan L, Williams J, et al. Covalent inhibitors of human monoacylglycerol lipase: ligand-assisted characterization of the catalytic site by mass spectrometry and mutational analysis. Chem Biol 2008; 15: 854-862.
43. Bahr BA. Long-term hippocampal slices: a model system for investigating synaptic mechanisms and pathologic processes. J Neurosci Res 1995; 42: 294-305.
44. Araújo IM, Gil JM, Carreira BP, et al. Calpain activation is involved in early caspase-independent neurodegeneration in the hippocampus following status epilepticus. J Neurochem 2008; 105: 666-676.
45. Bahr BA, Karanian DA, Makanji SS, Makriyannis A. Targeting the endocannabinoid system in treating brain disorders. Expert Opin Investig Drugs 2006; 15: 351-365.
46. Kawahara H, Drew GM, Christie MJ, Vaughan CW. Inhibition of fatty acid amide hydrolase unmasks CB1 receptor and TRPV1 channel-mediated modulation of glutamatergic synaptic transmission in midbrain periaqueductal grey. Br J Pharmacol 2011; 163: 1214-1222.
47. Coomber B, O'Donoghue MF, Mason R. Inhibition of endocannabinoid metabolism attenuates enhanced hippocampal neuronal activity induced by kainic acid. Synapse 2008; 62: 746-755.
48. Busquets-Garcia A, Puighermanal E, Pastor A, de la Torre R, Maldonado R, Ozaita A. Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses. Biol Psychiatry 2011; 70: 479-486.
49. De Paola V, Arber S, Caroni P. AMPA receptors regulate dynamic equilibrium of presynaptic terminals in mature hippocampal networks. Nat Neurosci 2003; 6: 491-500.
50. Gogolla N, Galimberti I, DePaola V, et al. Preparation of organotypic hippocampal slice cultures for long-term live imaging. Nat Protoc 2006; 1: 1165-1171.
51. Caba E, Bahr BA. Biphasic NF-κB activation in the excitotoxic hippocampus. Acta Neuropathol 2004; 108: 173-182.
52. Ryzhikov S, Bahr BA. Gephyrin alterations due to protein accumulation stress are reduced by the lysosomal modulator Z-Phe-Ala-diazomethylketone. J Mol Neurosci 2008; 34: 131-139.
53. Jourdi H, Hamo L, Oka T, Seegan A, Baudry M. BDNF mediates the neuroprotective effects of positive AMPA receptor modulators against MPP + -induced toxicity in cultured hippocampal and mesencephalic slices. Neuropharmacology 2009; 56: 876-885.
54. Wu Y, Liang S, Oda Y, et al. Truncations of amphiphysin I by calpain inhibit vesicle endocytosis during neural hyperexcitation. Embo J 2007; 26: 2981-2990.
55. David C, McPherson PS, Mundigl O, et al. A role of amphiphysin in synaptic vesicle endocytosis suggested by its binding to dynamin in nerve terminals. Proc Natl Acad Sci USA 1996; 93: 331-335.
56. Takei K, Slepnev VI, Haucke V, et al. Functional partnership between amphiphysin and dynamin in clathrin-mediated endocytosis. Nat Cell Biol 1999; 1: 33-39.
57. Slepnev VI, De Camilli P. Accessory factors in clathrin-dependent synaptic vesicle endocytosis. Nat Rev Neurosci 2000; 1: 161-172.
58. Akaike K, Tanaka S, Tojo H, et al. Kainic acid-induced dorsal and ventral hippocampal seizures in rats. Brain Res 2001; 900: 65-71.
59. Banke TG, Bowie D, Lee H, et al. Control of GluR1 AMPA receptor function by cAMP-dependent protein kinase. J Neurosci 2000; 20: 89-102.
60. Ehlers MD. Reinsertion or degradation of AMPA receptors determined by activity-dependent endocytic sorting. Neuron 2000; 28: 511-525.
61. Lee HK, Takamiya K, Han JS, et al. Phosphorylation of the AMPA receptor GluR1 subunit is required for synaptic plasticity and retention of spatial memory. Cell 2003; 112: 631-643.
62. Oh MC, Derkach VA, Guire ES, Soderling TR. Extrasynaptic membrane trafficking regulated by GluR1 serine 845 phosphorylation primes AMPA receptors for long-term potentiation. J Biol Chem 2006; 281: 752-758.
63. Bahr BA, Bendiske J, Brown QB, et al. Survival signaling and selective neuroprotection through glutamatergic transmission. Exp Neurol 2002; 174: 37-47.
64. Ortar G, Cascio MG, Moriello AS, et al. Carbamoyl tetrazoles as inhibitors of endocannabinoid inactivation: a critical revisitation. Eur J Med Chem 2008; 43: 62-72.
65. Bowman AL, Makriyannis A. Refined homology model of monoacylglycerol lipase: toward a selective inhibitor. J Comput Aided Mol Des 2009; 23: 799-806.
66. Long JZ, Nomura DK, Vann RE, et al. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci USA 2009; 106: 20270-20275.
67. Alexander SP, Kendall DA. The complications of promiscuity: endocannabinoid action and metabolism. Br J Pharmacol 2007; 152: 602-623.
68. Petzer JP, Castagnoli N, Jr., Schwarzschild MA, et al. Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease. Neurotherapeutics 2009; 6: 141-151.
69. Pretorius J, Malan SF, Castagnoli N, Jr., et al. Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E, E)-8-(4-phenylbutadien-1-yl)caffeine analogues. Bioorg Med Chem 2008; 16: 8676-8684.
70. Venneri A, McGeown WJ, Shanks MF. Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease. Neuroreport 2005; 16: 107-110.
71. Ballard CG. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur Neurol 2002; 47: 64-70.
72. Bartorelli L, Giraldi C, Saccardo M, et al. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease. Curr Med Res Opin 2005; 21: 1809-1818.
73. Zausinger S, Scholler K, Plesnila N, et al. Combination drug therapy and mild hypothermia after transient focal cerebral ischemia in rats. Stroke 2003; 34: 2246-2251.
74. Schmid-Elsaesser R, Hungerhuber E, Zausinger S, et al. Combination drug therapy and mild hypothermia: a promising treatment strategy for reversible, focal cerebral ischemia. Stroke 1999; 30: 1891-1899.